Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population‐based study

Autor: Xueqin Chen, Hui Yan, Mingge Zhou, Yuetao Wang, Xiaofei Mo
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Oncology
Male
Cancer Research
Neoplasms
Radiation-Induced
medicine.medical_treatment
Brachytherapy
radiation therapy
Prostate cancer
Epidemiology
Stage (cooking)
Research Articles
RC254-282
Leukemia
Radiation-Induced
Prostatectomy
Lymphoma
Non-Hodgkin
Hazard ratio
Age Factors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Neoplasms
Second Primary
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma
prostate cancer
Hodgkin Disease
Leukemia
Myeloid
Acute
Hematologic Neoplasms
Leukemia
Monocytic
Acute
Regression Analysis
Cancer Prevention
Research Article
medicine.medical_specialty
Risk Assessment
Internal medicine
Leukemia
Myelogenous
Chronic
BCR-ABL Positive
medicine
Confidence Intervals
Humans
Radiology
Nuclear Medicine and imaging
Aged
Proportional Hazards Models
prostatectomy
business.industry
Prostatic Neoplasms
medicine.disease
Leukemia
Lymphocytic
Chronic
B-Cell
Confidence interval
Radiation therapy
Relative risk
hematologic malignancy
business
SEER Program
Zdroj: Cancer Medicine, Vol 10, Iss 15, Pp 5338-5346 (2021)
Cancer Medicine
ISSN: 2045-7634
Popis: Background Patients with prostate cancer (PC) are at a high risk of developing secondary hematologic malignancies (SHMs) after radiation therapy (RT), while no study has assessed the relationship of different treatment modalities with the occurrence of SHMs after PC at early stage. This study aimed to investigate the risks of developing SHMs in patients with T1/T2 PC undergoing different treatment modalities. Methods Patients with T1/T2 PC were identified from the Surveillance, Epidemiology, and End Results database. Competing risk regression (CRR) model was performed to evaluate the hazard ratios (HRs) of developing SHMs. As SHMs scarcely occur, the relative risk (RR) analysis was employed to compare the risks of different treatment modalities associating with the development of SHMs. Results The CRR analysis showed that undergoing RT was associated with a higher risk of developing SHMs (external beam radiation therapy [EBRT]: HR = 1.21, 95% confidence interval [CI]: 1.10–1.34; radioactive implant [RI]: HR = 1.20, 95% CI: 1.06–1.36). As for different types of SHMs, EBRT, and RI were correlated with decreased risks of developing CLL (RR = 0.67, 0.72; 95% CI: 0.53–0.85, 0.54–0.96, respectively), but with the increased risks of developing NHL (RR = 1.18, 1.23; 95% CI: 1.02–1.35, 1.05–1.44, respectively); EBRT also showed increased risks of developing acute/ chronic myeloid leukemia (AML/CML, RR = 1.54, 1.56; 95% CI: 1.16–2.03,1.05–2.33, respectively); No increased risk of developing SHMs was detected in patients who only underwent prostatectomy. Conclusions Although RT was found to be associated with the increased risks of developing SHMs in patients with T1/T2 PC, this finding cannot be extended to diverse types of SHMs. RT was correlated with the increased risks of the development of NHL, AML, and CML, but with the decreased risk of developing CLL. Prostatectomy did not increase the risk of developing SHMs.
Our study used a large population‐based analysis to estimate the risk of different radiation therapy modalities for second hematologic malignancies developing after T1/2 prostate cancer. External beam radiation therapy and radioactive implant were correlated with increased risks of acute/chronic myeloid leukemia but decreased risk of chronic lymphocytic leukemia. The impact of radiation therapy on second hematologic malignancies developing after T1/2 prostate cancer was different in various types of hematologic malignancies.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje